Federal Circuit Affirms Invalidity of Alzheon’s Alzheimer’s Drug Patent in PTAB Appeal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Risen (Suzhou) Pharma Tech Co., Ltd. v. Alzheon, Inc. |
| Case Number | 22-2232 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from PTAB |
| Duration | Sept 2022 – March 2024 1 year 6 months |
| Outcome | Patent Unpatentable / Invalidated |
| Patents at Issue | |
| Technology Area | Isotope-enriched 3-APS derivatives |
Case Overview
The Parties
⚖️ Petitioner
China-based pharmaceutical technology company with operations relevant to active pharmaceutical ingredient synthesis and drug development.
🛡️ Patent Owner
U.S.-based clinical-stage biopharmaceutical company focused on Alzheimer’s disease therapeutics, leveraging isotope-enriched 3-APS formulations.
The Patent at Issue
This landmark case involved U.S. Patent No. 10,472,323 B2, covering isotope-enriched 3-amino-1-propanesulfonic acid (3-APS) derivatives — a compound class central to Alzheimer’s disease drug development. Isotope enrichment, particularly deuterium substitution, is a recognized strategy in pharmaceutical development to modify a drug’s metabolic profile, potentially improving efficacy or reducing side effects.
- • US10,472,323 B2 — Isotope-enriched 3-amino-1-propanesulfonic acid derivatives
Developing a new drug compound?
Check if your pharmaceutical derivative might infringe existing patents before clinical trials.
The Verdict & Legal Analysis
Outcome
The Federal Circuit **affirmed** the finding of **unpatentability** of U.S. Patent No. 10,472,323 B2. No damages were at issue, consistent with the nature of an invalidity/cancellation proceeding rather than an infringement action. The affirmance extinguishes Alzheon’s patent rights in the challenged claims, rendering the patent unenforceable as a matter of law.
Key Legal Issues
The Federal Circuit’s affirmance validates the underlying invalidity/cancellation action, which most commonly rests on **obviousness under 35 U.S.C. § 103**. For isotope-enriched pharmaceutical derivatives, the central validity question is whether deuterium substitution of a known compound — here, 3-APS (tramiprosate) — would have been obvious to a person of ordinary skill in the art (POSITA) given prior art disclosing both the parent compound and known deuterium-labeling techniques.
The decision reinforces the **Federal Circuit’s demanding patentability standard** for isotopically labeled drug derivatives. Patent applicants in the deuterium drug space must demonstrate more than structural novelty; they must show unexpected results, distinct pharmacological profiles, or non-obvious technical advantages over the parent compound and known labeling art.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical compound development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View related compound patents in this technology space
- See which companies are most active in deuterium drug patents
- Understand obviousness trends for isotopically labeled compounds
🔍 Check My Compound’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical compound or derivative.
- Input your compound structure or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Obviousness Risk
Isotope-enriched known compounds
Related Art Exist
On parent compound and labeling techniques
IPR Effectiveness
Demonstrated for derivative patents
✅ Key Takeaways
Federal Circuit affirmed PTAB’s unpatentability finding for isotope-enriched pharmaceutical derivative (US10,472,323 B2).
Search related case law →Deuterium substitution of known compounds faces heightened obviousness scrutiny absent unexpected results evidence.
Explore obviousness precedents →IPR remains a powerful and strategically efficient invalidity mechanism in pharmaceutical patent disputes.
Analyze IPR success rates →Frequently Asked Questions
U.S. Patent No. 10,472,323 B2, covering isotope-enriched 3-amino-1-propanesulfonic acid derivatives and their pharmaceutical uses (Application No. US15/476,255).
The Federal Circuit affirmed an invalidity/cancellation determination, consistent with an IPR proceeding where patentability — most likely on obviousness grounds — was successfully challenged by Risen (Suzhou) Pharma Tech Co., Ltd.
The decision reinforces that isotopic labeling of known pharmaceutical compounds requires demonstrated non-obvious advantages to sustain patentability, raising the evidentiary bar for similar patents across the CNS and broader pharmaceutical sectors.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States Court of Appeals for the Federal Circuit — Case No. 22-2232
- USPTO Patent Center — US10,472,323 B2
- PACER — Case No. 22-2232
- Cornell Legal Information Institute — 35 U.S.C. § 103
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.